Oxytocic Pharmaceuticals Market to worth US$ 157.6 million by 2026 End
Future Market Insights has announced the addition of the “Oxytocic Pharmaceuticals Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering.
Future Market Insights has announced the addition of the “Oxytocic Pharmaceuticals Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong>: Global Industry Analysis<br />
and Opportunity Assessment 2016-<strong>2026</strong><br />
May 2017<br />
Report Id : REP-GB-1445<br />
Status : Jan-2017<br />
Category : Healthcare, <strong>Pharmaceuticals</strong> & Medical Devices<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved
About<br />
Future <strong>Market</strong> Insights<br />
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, cus<strong>to</strong>m<br />
research reports, and consulting services. We deliver a complete packaged solution, which<br />
combines current market intelligence, statistical anecdotes, technology inputs, valuable growth<br />
insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC,<br />
ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy,<br />
Technology, Healthcare, and Retail.<br />
We have a global presence with delivery centers across India specializing in providing global<br />
research reports and country research reports. FMI is headquartered out of London, U.K., with a<br />
state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning<br />
from every corner of the world <strong>to</strong> distill it <strong>to</strong> one thing – the perfect solution for our client.<br />
Research Capabilities<br />
Sec<strong>to</strong>r Coverage<br />
<br />
<br />
<br />
<br />
Cus<strong>to</strong>mized Research<br />
Syndicated Research<br />
Investment Research<br />
Social Media Research<br />
<br />
<br />
<br />
<br />
Au<strong>to</strong>motive and Transportation<br />
Electronics, Semiconduc<strong>to</strong>r, and ICT<br />
Retail and Consumer Products<br />
Industrial Au<strong>to</strong>mation and Equipment<br />
<br />
<br />
<br />
<br />
Chemicals & Materials<br />
Food and Beverages<br />
Services and Utilities<br />
Energy, Mining, Oil, and Gas<br />
Cus<strong>to</strong>mized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
2
Research Methodology (1/2)<br />
Systematic Research Approach<br />
<strong>Market</strong> profiling<br />
Formulating discussion guide<br />
Developing list of respondents<br />
Data collection<br />
Data validation<br />
4<br />
5<br />
3<br />
1<br />
2<br />
In-depth secondary research is used <strong>to</strong><br />
ascertain overall market size, <strong>to</strong>p<br />
industry players, <strong>to</strong>p products, industry<br />
associations, etc.<br />
PMR formulates a detailed discussion<br />
guide <strong>to</strong> conduct expert and industry<br />
interviews<br />
PMR develops a list of industry players<br />
(manufacturers), distribu<strong>to</strong>rs, retailers<br />
and industry experts<br />
PMR conducts interviews with industry<br />
experts, industry players, distribu<strong>to</strong>rs<br />
and retailers<br />
Data is validated <strong>by</strong> triangulation<br />
method, wherein secondary, primary<br />
and PMR analysis contribute <strong>to</strong> the final<br />
data<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Data<br />
Collection<br />
Data Filter<br />
& Analysis<br />
Identifying key opinion leaders<br />
Questionnaire design<br />
In-depth interviews<br />
Coverage across value chain<br />
<strong>Market</strong> participants<br />
Key strengths<br />
Product portfolio<br />
Mapping as per value chain<br />
Key focus segments<br />
A<br />
Primary<br />
Research<br />
C<br />
Company<br />
Analysis<br />
Research &<br />
Intelligence<br />
SOLUTION<br />
Actionable<br />
Insights<br />
B<br />
Desk<br />
Research<br />
<br />
<br />
<br />
<br />
<br />
<br />
Business<br />
Solution<br />
Key industry experts<br />
Channel study<br />
Developments<br />
<strong>Market</strong> dynamics<br />
Products<br />
Conclusions<br />
Data analysis<br />
6<br />
Data is scrutinized using MS-Excel <strong>to</strong><br />
obtain qualitative and quantitative<br />
insights about the industry<br />
Primary Research #<br />
Secondary Research #<br />
Paid Publications#<br />
Insights<br />
7<br />
PMR delivers industry insights and<br />
information in the required format<br />
(PDF)<br />
<br />
<br />
<br />
<br />
Linkedin<br />
Zoominfo<br />
Salesforce<br />
Avention<br />
<br />
<br />
<br />
<br />
Company websites<br />
Company annual<br />
reports<br />
White papers<br />
Financial reports<br />
<br />
<br />
<br />
<br />
Factiva<br />
GBI<br />
Genios<br />
Meltwater<br />
# includes sources of databases<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
3
Europe Hospital Capacity Management Solutions <strong>Market</strong><br />
Synthetic <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> will Amass Nearly <strong>US$</strong> 150 Million Revenues <strong>by</strong> <strong>2026</strong>-end<br />
Though synthetic oxy<strong>to</strong>cin is chemically equivalent <strong>to</strong> naturally-occurring oxy<strong>to</strong>cin, their pharmaceutical<br />
functions for aiding women in labour are quite distinctive. Medical professionals from around the world<br />
will continue <strong>to</strong> recommend synthetic-based oxy<strong>to</strong>cic pharmaceuticals over natural since oxy<strong>to</strong>cic<br />
pharmaceuticals originating from synthetic sources can boost the momentum of decelerated labour <strong>by</strong> IV<br />
administration. More than 90% of the global market revenues for oxy<strong>to</strong>cic pharmaceuticals will be<br />
harvested from the sales of oxy<strong>to</strong>cic pharmaceuticals originating from synthetic sources. By the end of<br />
<strong>2026</strong>, an estimated <strong>US$</strong> 148.9 <strong>million</strong> revenues will be emanated from the global sales of synthetic<br />
oxy<strong>to</strong>cic pharmaceuticals.<br />
Future <strong>Market</strong> Insights’ published report on the global oxy<strong>to</strong>cic pharmaceuticals market estimates that<br />
the market, which is presently valued at <strong>US$</strong> 62.2 <strong>million</strong>, will expand at an impressive 9.7% CAGR <strong>to</strong><br />
reach <strong>US$</strong> <strong>157.6</strong> <strong>million</strong> value <strong>by</strong> <strong>2026</strong>-end. In the report, titled “<strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong>:<br />
Global Industry Analysis & Opportunity Assessment, 2016-<strong>2026</strong>,” Future <strong>Market</strong> Insights projects that<br />
the global market for oxy<strong>to</strong>cic pharmaceuticals will remain highly fragmented due <strong>to</strong> higher prevalence of<br />
local players as opposed <strong>to</strong> multinationals and conglomerates. Nevertheless, global pharmaceutical<br />
industry leaders such as Pfizer Inc., Novartis AG, Baxter Healthcare Corporation, and Teva Pharmaceutical<br />
Industries Ltd. are also partaking in the global oxy<strong>to</strong>cic pharmaceuticals market. Other leading<br />
manufacturers of oxy<strong>to</strong>cic pharmaceuticals include Biofutura Pharma SpA, Ferring BV, and Fresenius Kabi<br />
AG.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 4
Europe Hospital Capacity Management Solutions <strong>Market</strong><br />
Global <strong>Oxy<strong>to</strong>cic</strong> pharmaceuticals <strong>Market</strong>: Regional Analysis<br />
The need for oxy<strong>to</strong>cic pharmaceuticals in the world will always remain contingent <strong>to</strong> the rise in pregnancy<br />
incidences and birth rate. Various parts of the world exhibit diverse birth rate, which incidentally drives<br />
the growth of their oxy<strong>to</strong>cic pharmaceuticals market, accordingly. In North America, oxy<strong>to</strong>cic<br />
pharmaceuticals are majorly used for postpartum haemorrhage, which is one of the most-prominent<br />
indication among labouring women in the US and Canada. However, China is expected <strong>to</strong> remain the<br />
largest market for oxy<strong>to</strong>cic pharmaceuticals in the world. Considering the country’s exploding birth rate,<br />
China’s oxy<strong>to</strong>cic pharmaceuticals market will be valued over <strong>US$</strong> 55 <strong>million</strong> <strong>by</strong> <strong>2026</strong>-end, expanding at<br />
9.8% CAGR. In 2016, Japan’s oxy<strong>to</strong>cic pharmaceuticals revenues amounted <strong>to</strong> an estimated <strong>US$</strong> 1.7<br />
<strong>million</strong>, while the oxy<strong>to</strong>cic pharmaceuticals market in Asia-Pacific excluding Japan & China (APEJC) region<br />
has been estimated <strong>to</strong> account for nearly 20% of global revenues.<br />
Global <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong>: Research Highlights<br />
Licensing agreements for development of newer oxy<strong>to</strong>cic pharmaceuticals is rampantly boosting the<br />
global market revenues, profiting local players as well as industry leaders.<br />
Surging prevalence of labour induction procedures for child births will continue promoting the use of<br />
oxy<strong>to</strong>cic pharmaceuticals throughout the forecast period.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 5
Europe Hospital Capacity Management Solutions <strong>Market</strong><br />
The global oxy<strong>to</strong>cic pharmaceuticals revenues, however, are projected <strong>to</strong> witness an inhibited growth<br />
on the account of rising preference <strong>to</strong> alternative drugs such as magnesium sulphate and misopros<strong>to</strong>l.<br />
India’s contribution <strong>to</strong> the APEJC oxy<strong>to</strong>cic pharmaceuticals market is predicted <strong>to</strong> reach nearly 60% <strong>by</strong><br />
the end of <strong>2026</strong>.<br />
More than 22,000 thousand units of oxy<strong>to</strong>cic pharmaceuticals will be sold globally for treating labour<br />
arrest over the forecast period.<br />
Hospitals will remain the largest end-user of oxy<strong>to</strong>cic pharmaceuticals in the world, revenues from<br />
which will expand beyond 12% CAGR.<br />
A majority of medical professionals in the world will recommend intravenous administration of<br />
oxy<strong>to</strong>cic pharmaceuticals, accounting for more than two-third of global market revenues <strong>by</strong> the end of<br />
<strong>2026</strong>.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 6
Table of Content<br />
1. Executive Summary<br />
2. <strong>Market</strong> Introduction<br />
2.1. <strong>Market</strong> Definition<br />
2.2. <strong>Market</strong> Taxonomy<br />
3. Global <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong> Analysis Scenario<br />
4. <strong>Market</strong> Dynamics<br />
3.1. <strong>Market</strong> Size (<strong>US$</strong> Mn) and Forecast<br />
3.1.1. <strong>Market</strong> Size and Y-o-Y Growth<br />
3.1.2. Absolute $ Opportunity<br />
4.1. Macro-economic Fac<strong>to</strong>rs<br />
4.2. Drivers<br />
4.2.1. Supply Side<br />
4.2.2. Demand Side<br />
4.3. Restraints<br />
4.4. Opportunity<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
7
Table of Content<br />
4.5. Number of procedures <strong>by</strong> Indications per region (2015-<strong>2026</strong>)<br />
4.6. Number of procedures <strong>by</strong> <strong>End</strong> User per region (2015-<strong>2026</strong>)<br />
4.7. Number of cervical ripening procedures <strong>by</strong> region (2015)<br />
4.8. Comparative drugs list other than Oxy<strong>to</strong>cin<br />
5. Global <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong> Analysis and Forecasts, By Indication<br />
5.1. Introduction<br />
5.2. Basis Point Share (BPS) Analysis By Indication Type<br />
5.3. Y-o-Y Growth Projections By Indication Type<br />
5.4. <strong>Market</strong> Value Forecast By Indication, 2016–<strong>2026</strong><br />
5.4.1. Abortion Induced Incomplete<br />
5.4.2. Inevitable Abortion<br />
5.4.3. Postpartum Hemorrhage<br />
5.4.4. Labor Induction<br />
5.4.5. Labor Arrest<br />
5.5. <strong>Market</strong> Attractiveness By Indication<br />
6. Global <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong> Analysis and Forecasts, By <strong>End</strong> User<br />
6.1. Introduction<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
8
Table of Content<br />
6.2. Basis Point Share (BPS) Analysis By <strong>End</strong> User<br />
6.3. Y-o-Y Growth Projections By <strong>End</strong> User<br />
6.4. <strong>Market</strong> Value Forecast By <strong>End</strong> User, 2016–<strong>2026</strong><br />
6.4.1. Hospitals<br />
6.4.2. Maternity Clinics<br />
6.5. <strong>Market</strong> Attractiveness By <strong>End</strong> User<br />
7. Global <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong> Analysis and Forecasts, By Route of Administration<br />
7.1. Introduction<br />
7.2. Basis Point Share (BPS) Analysis By Route of Administration<br />
7.3. Y-o-Y Growth Projections By Route of Administration<br />
7.4. <strong>Market</strong> Value Forecast By Route of Administration, 2016–<strong>2026</strong><br />
7.4.1. Intravenous Infusion/Injection<br />
7.4.2. Intramuscular Injection<br />
7.5. <strong>Market</strong> Attractiveness By Route of Administration<br />
8. Global <strong>Oxy<strong>to</strong>cic</strong> <strong>Pharmaceuticals</strong> <strong>Market</strong> Analysis and Forecasts, By Source of Origin<br />
8.1. Introduction<br />
8.2. Basis Point Share (BPS) Analysis By Source of Origin<br />
8.3. Y-o-Y Growth Projections By Source of Origin<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
9
Table of Content<br />
8.4. <strong>Market</strong> Value Forecast By Source of Origin, 2016–<strong>2026</strong><br />
8.4.1. Synthetic Oxy<strong>to</strong>cin Derivative<br />
8.4.2. Natural Oxy<strong>to</strong>cin (Animal Pituitary Extract)<br />
8.5. <strong>Market</strong> Attractiveness By Source of Origin<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
10
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new <strong>to</strong>pics email us on:<br />
sales@futuremarketinsights.com<br />
For media queries, contact the press office at<br />
press@futuremarketinsights.com<br />
For other queries contact:<br />
Hari. T (Sr. Manager - Global Business Development)<br />
Future <strong>Market</strong> Insights: 3rd Floor,<br />
207 Regent Street, London W1B 3HH<br />
T: +44 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com<br />
Thank You<br />
Future <strong>Market</strong> Insights Global & Consulting Private Limited (FMI)<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved<br />
11
Change language